Regeneron Acquires 23andMe’s DNA Testing Business

---

Full Story

Regeneron Pharmaceuticals has acquired 23andMe’s DNA testing business and most assets from bankruptcy, aiming to use genetic data to develop new medicines. The deal transfers millions of customers’ DNA data to a pharmaceutical company. This move raises questions about privacy and the use of personal genetic information.

23andMe, once a leader in consumer DNA testing, faced financial struggles. Regeneron’s acquisition includes data from millions of customer profiles.

MEDIA REPORTING

See how news sources on all sides are covering this story.

Left 31% | Right 23% | Center 38% | Unrated 8%

The Context

The pharmaceutical company plans to mine this data for drug development insights. Genetic data can reveal patterns useful for crafting targeted therapies.

Bankruptcy allowed Regeneron to purchase 23andMe’s assets at a reduced cost. The deal marks a shift from consumer testing to pharmaceutical research.

DNA data is highly sensitive, protected under U.S. privacy laws like HIPAA. The transfer raises concerns about how Regeneron will safeguard this information.

Regeneron has not detailed its plans for managing customer data privacy. Past data breaches in similar industries heighten public wariness.

Some support the deal, citing potential medical breakthroughs from genetic research. Others fear it risks misuse of personal data without consent.

Privacy advocates urge stronger regulations on genetic data use. Supporters argue pharmaceutical advances justify the acquisition’s benefits.